Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide

Click to increase image sizeClick to decrease image size

Ethical approval

This is an observational study. The Regional Scientific Ethical Committee of The Capital Region of Denmark has confirmed that no ethical approval is required.

Authors’ contribution

All authors contributed to the study's conception and design. Material preparation, data collection and analysis were performed by Annika Marie Ørting, Malene Martini Clausen, and Seppo W. Langer. The first draft of the manuscript was written by Annika Marie Ørting and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

RHP: Speaker fee: Medtronic, AMBU, Medela, and AstraZeneca. Advisory board: AstraZeneca, Roche and BMS.

SWL: Advisory board, research collaboration, speaker fee: Roche, Merck, Amgen, AbbVie, Jannsen Pharma, Boehringer-Ingelheim.

Data availability statement

Data available on request from the authors.

Additional information

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.